HC Wainwright Analysts Increase Earnings Estimates for ELTX

Elicio Therapeutics, Inc. (NASDAQ:ELTX) – Research analysts at HC Wainwright boosted their Q2 2026 EPS estimates for shares of Elicio Therapeutics in a research note issued on Monday, June 15th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.45) for the quarter, up from their prior estimate of ($0.46). HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Elicio Therapeutics’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Elicio Therapeutics’ Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.39) EPS and FY2026 earnings at ($1.82) EPS.

ELTX has been the topic of a number of other reports. Wall Street Zen cut Elicio Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. LADENBURG THALM/SH SH assumed coverage on shares of Elicio Therapeutics in a report on Wednesday, April 15th. They issued a “buy” rating and a $20.00 price target for the company. B. Riley Financial started coverage on shares of Elicio Therapeutics in a report on Wednesday, June 10th. They set a “buy” rating and a $27.00 target price for the company. JonesTrading reiterated a “hold” rating on shares of Elicio Therapeutics in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Elicio Therapeutics in a report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Elicio Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.75.

Elicio Therapeutics Trading Down 32.4%

Shares of NASDAQ ELTX opened at $2.76 on Wednesday. Elicio Therapeutics has a 12-month low of $2.66 and a 12-month high of $16.00. The company has a market cap of $52.69 million, a price-to-earnings ratio of -1.15 and a beta of 1.13. The company has a current ratio of 2.24, a quick ratio of 2.24 and a debt-to-equity ratio of 5.75. The stock’s 50 day simple moving average is $11.08 and its 200 day simple moving average is $9.88.

Elicio Therapeutics (NASDAQ:ELTX) last issued its earnings results on Monday, May 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16).

Hedge Funds Weigh In On Elicio Therapeutics

Large investors have recently made changes to their positions in the business. CIBC Bancorp USA Inc. acquired a new stake in shares of Elicio Therapeutics during the 3rd quarter valued at $350,000. Millennium Management LLC acquired a new position in shares of Elicio Therapeutics in the third quarter worth $250,000. Squarepoint Ops LLC purchased a new stake in shares of Elicio Therapeutics during the fourth quarter worth $133,000. Occudo Quantitative Strategies LP purchased a new stake in shares of Elicio Therapeutics during the fourth quarter worth $126,000. Finally, Jane Street Group LLC purchased a new stake in shares of Elicio Therapeutics during the first quarter worth $92,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Key Headlines Impacting Elicio Therapeutics

Here are the key news stories impacting Elicio Therapeutics this week:

• Positive Sentiment: HC Wainwright reportedly raised its price target and reiterated a buy rating, suggesting some analysts still see upside if the development strategy improves. Analyst price target update
• Neutral Sentiment: JonesTrading reaffirmed a hold rating, indicating a wait-and-see stance after the clinical update. JonesTrading rating reaffirmed
• Neutral Sentiment: The company also outlined a refined Phase 3 development strategy, but that longer-term plan has been overshadowed by the Phase 2 miss. Phase 2 results and Phase 3 strategy
• Negative Sentiment: The main catalyst is the failed AMPLIFY-7P trial endpoint, which directly undermines the investment case for ELI-002 7P and triggered a sharp selloff. Reuters report on trial miss
• Negative Sentiment: Law firms have already announced investigations into whether Elicio properly disclosed the trial setback, adding litigation risk and more pressure on the shares. Investigation announcement

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.